Electroconvulsive shock (ECS) and H-endorphin-induced analgesia: unconventional interactions with naloxone. 1982

G Urca, and A Harouni, and Y Sarne

Acute administration of electroconvulsive shock (ECS) has been shown previously to produce potent analgesia which is only partially reversed by naloxone but shows almost complete tolerance after both repeated ECS and chronic morphine administration. In an attempt to elucidate the underlying basis of ECS analgesia it was recently compared with the analgesic effect of a newly identified opioid, humoral (H)-endorphin. Intracerebroventricular (i.c.v.) injection of H-endorphin to rats produces a dose-related analgesic effect as measured by the tail flick method. Furthermore, 4 days of daily i.c.v. injections of 40 microgram of morphine resulted in complete tolerance to the analgesic effect of H-endorphin. However, naloxone only caused a partial reversal of H-endorphin analgesia. Surprisingly only the lower dose of 1 mg/kg exerted a significant antagonistic effect while a higher dose of 10 mg/kg of the antagonist was without effect. A similar unconventional profile of the effect of naloxone could be seen with ECS analgesia. Here, pretreatment with 1 mg/kg of naloxone significantly attenuated analgesia, whereas administration of 10 mg/kg of the antagonist was without effect. In contrast, catalepsy measured in the same animals was not affected by 1 mg/kg of naloxone but increasing the dose to 10 mg/kg produced a significant attenuation of ECS catalepsy. The opioid nature of H-endorphin analgesia on one hand and the unconventional dose relation with naloxone of both H-endorphin and ECS analgesia on the other hand, suggests the involvement of this opioid in analgesia induced by ECS. Furthermore, it is possible that other behavioral manipulations which display only partial opiate characteristics may be mediated by H-endorphin or similar endogenous substances.

UI MeSH Term Description Entries
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D002375 Catalepsy A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. The limbs tend to remain in whatever position they are placed (waxy flexibility). Catalepsy may be associated with PSYCHOTIC DISORDERS (e.g., SCHIZOPHRENIA, CATATONIC), nervous system drug toxicity, and other conditions. Cerea Flexibilitas,Flexibility, Waxy,Anochlesia,Anochlesias,Catalepsies,Flexibilitas, Cerea,Flexibilities, Waxy,Waxy Flexibilities,Waxy Flexibility
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004597 Electroshock Induction of a stress reaction in experimental subjects by means of an electrical shock; applies to either convulsive or non-convulsive states. Electroconvulsive Shock,Electroconvulsive Shocks,Electroshocks,Shock, Electroconvulsive,Shocks, Electroconvulsive
D004723 Endorphins One of the three major groups of endogenous opioid peptides. They are large peptides derived from the PRO-OPIOMELANOCORTIN precursor. The known members of this group are alpha-, beta-, and gamma-endorphin. The term endorphin is also sometimes used to refer to all opioid peptides, but the narrower sense is used here; OPIOID PEPTIDES is used for the broader group. Endorphin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000698 Analgesia Methods of PAIN relief that may be used with or in place of ANALGESICS. Analgesias

Related Publications

G Urca, and A Harouni, and Y Sarne
March 1981, Brain research,
G Urca, and A Harouni, and Y Sarne
January 1989, Polish journal of pharmacology and pharmacy,
G Urca, and A Harouni, and Y Sarne
April 1982, Behavioral and neural biology,
G Urca, and A Harouni, and Y Sarne
December 1976, Life sciences,
G Urca, and A Harouni, and Y Sarne
April 1984, Behavioral neuroscience,
G Urca, and A Harouni, and Y Sarne
January 1996, Acta physiologica Hungarica,
G Urca, and A Harouni, and Y Sarne
October 1985, Neuroscience letters,
G Urca, and A Harouni, and Y Sarne
November 2004, Indian journal of experimental biology,
G Urca, and A Harouni, and Y Sarne
January 1990, Convulsive therapy,
Copied contents to your clipboard!